BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song T, Liang X, Fang M, Wu S. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev Anticancer Ther 2015;15:1157-69. [PMID: 26235427 DOI: 10.1586/14737140.2015.1074041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao J, Lei T, Zhang T, Chen X, Dong J, Guan Y, Wang J, Wei H, Er P, Han D, Wei X, Guo Z, Du Q, Wang J, Liu N, Song Y, Yuan Z, Zhao L, Zhang W, Pang Q, Wang P. The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinoma. Ann Transl Med 2020;8:1160. [PMID: 33241009 DOI: 10.21037/atm-20-4366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 De B, Rhome R, Doucette J, Buckstein M. Dose escalation of definitive radiation is not associated with improved survival for cervical esophageal cancer: a National Cancer Data Base (NCDB) analysis. Diseases of the Esophagus 2017;30:1-10. [DOI: 10.1093/dote/dow037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
3 Li C, Wang X, Wang L, Chen J, Zhang W, Pang Q, Zhao Y, Sun X, Zhang K, Li G, Li L, Qiao X, Liu M, Wang Y, Deng L, Wang W, Bi N, Zhang T, Deng W, Ni W, Chang X, Han W, Zhou Z, Liang J, Feng Q, Wang L, Chen D, Lv J, Zhu S, Han C, Xiao Z. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta Oncol 2021;60:627-34. [PMID: 33793382 DOI: 10.1080/0284186X.2021.1902564] [Reference Citation Analysis]
4 Chen H, Zhou L, Yang Y, Yang L, Chen L. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma. Med Sci Monit 2018;24:4183-91. [PMID: 29915168 DOI: 10.12659/MSM.910326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Fan CY, Su YF, Huang WY, Chao HL, Lin KT, Lin CS. Definitive radiotherapy dose escalation with chemotherapy for treating non-metastatic oesophageal cancer. Sci Rep 2018;8:12877. [PMID: 30150679 DOI: 10.1038/s41598-018-31302-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li C, Wang X, Wang X, Han C, Wang P, Pang Q, Chen J, Sun X, Wang L, Zhang W, Lin Y, Ge X, Zhou Z, Ni W, Chang X, Liang J, Deng L, Wang W, Zhao Y, Xiao Z. A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. BMC Cancer 2019;19:397. [PMID: 31036088 DOI: 10.1186/s12885-019-5544-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gao LR, Wang X, Han W, Deng W, Li C, Wang X, Zhao Y, Ni W, Chang X, Zhou Z, Deng L, Wang W, Liu W, Liang J, Zhang T, Bi N, Wang J, Zhai Y, Feng Q, Lv J, Li L, Xiao Z. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer 2020;20:901. [PMID: 32962674 DOI: 10.1186/s12885-020-07387-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Zhang W, Zhao J, Han W, Zhang H, Wang X, Li C, Chen J, Wang X, Zhao Y, Qiao X, Zhou Z, Han C, Zhu S, Shen W, Wang L, Ge X, Sun X, Zhang K, Hu M, Li L, Hao C, Li G, Xu Y, Wang Y, Lu N, Liu M, Qian S, Xiao Z, Wang P, Pang Q. Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). Ann Transl Med 2020;8:1140. [PMID: 33240989 DOI: 10.21037/atm-20-4672] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Li C, Tan L, Liu X, Wang X, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Wang X, Bi N, Deng L, Wang W, Zhang T, Ni W, Chang X, Han W, Gao L, Wang S, Xiao Z. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. Thorac Cancer 2021;12:1831-40. [PMID: 33949784 DOI: 10.1111/1759-7714.13971] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Ren X, Wang L, Han C, Ren L. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma. Radiother Oncol 2018;129:293-9. [PMID: 30270099 DOI: 10.1016/j.radonc.2018.09.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
11 Luo Y, Mao Q, Wang X, Yu J, Li M. Radiotherapy for esophageal carcinoma: dose, response and survival. Cancer Manag Res 2018;10:13-21. [PMID: 29343986 DOI: 10.2147/CMAR.S144687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
12 Xiao L, Czito BG, Pang Q, Hui Z, Jing S, Shan B, Wang J. Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review. J Cancer 2020;11:4605-13. [PMID: 32489478 DOI: 10.7150/jca.44447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Zheng R, Liu Y, Zhang X, Zhao P, Deng Q. miRNA-200c enhances radiosensitivity of esophageal cancer by cell cycle arrest and targeting P21. Biomed Pharmacother. 2017;90:517-523. [PMID: 28402920 DOI: 10.1016/j.biopha.2017.04.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
14 Chung TR, Kim JH, Lee IJ, Cho Y, Kim JW, Lee CG, Jung DH, Park JJ, Youn YH, Park H. Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement. Dig Liver Dis 2019;51:1610-6. [PMID: 31175014 DOI: 10.1016/j.dld.2019.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Ji H, Cao M, Ren K, Sun N, Wang W, Zhu Q, Zang Q, Jiang Z. Expression and Clinicopathological Significance of Mel-18 and Bmi-1 in Esophageal Squamous Cell Carcinoma. Technol Cancer Res Treat 2017;16:828-34. [PMID: 28425347 DOI: 10.1177/1533034617705055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
16 Kim HJ, Suh YG, Lee YC, Lee SK, Shin SK, Cho BC, Lee CG. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. Cancer Res Treat 2017;49:669-77. [PMID: 27737537 DOI: 10.4143/crt.2016.354] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
17 Li C, Ni W, Wang X, Zhou Z, Deng W, Chang X, Chen D, Feng Q, Liang J, Wang X, Deng L, Wang W, Bi N, Zhang T, Xiao Z. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiat Oncol 2019;14:48. [PMID: 30876442 DOI: 10.1186/s13014-019-1249-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
18 Kwong DLW, Chan WWL, Lam KO. Radiotherapy for Cervical Esophageal Squamous Cell Carcinoma. Methods Mol Biol 2020;2129:295-305. [PMID: 32056186 DOI: 10.1007/978-1-0716-0377-2_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sun X, Wang L, Wang Y, Kang J, Jiang W, Men Y, Hui Z. High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis. Front Oncol 2020;10:1222. [PMID: 32850362 DOI: 10.3389/fonc.2020.01222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
20 Dong J, Zhang W, Zhang T, Chen X, Zhao J, Zeng Y, Chen Y, Wei X, Lei T, Wang P, Zhao L, Wang J, Yuan Z, Song Y, Liu N, Wang K, Pang Q. Baseline nutritional status could be a predictor for radiation esophagitis in esophageal cancer patients undergoing radiotherapy. Ann Transl Med 2020;8:1148. [PMID: 33240997 DOI: 10.21037/atm-20-4078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Jing Z, Chen T, Zhang X, Wu S. Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer. Cancer Sci 2017;108:1828-33. [PMID: 28665042 DOI: 10.1111/cas.13308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
22 Lv S, Fang M, Yang J, Zhan W, Jia Y, Xu H, Song T. Long-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer. Onco Targets Ther 2016;9:5389-97. [PMID: 27660461 DOI: 10.2147/OTT.S107668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Song T, Zhang X, Fang M, Zhao R, Wu S. Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: a prospective phase II trial. Cancer Med 2016;5:3371-7. [PMID: 27925455 DOI: 10.1002/cam4.897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis 2017;9:S792-8. [PMID: 28815076 DOI: 10.21037/jtd.2017.05.05] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
25 Ono T. Review of clinical results of charged-particle therapy for esophageal cancer. Esophagus 2021;18:33-40. [PMID: 32654019 DOI: 10.1007/s10388-020-00759-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Luo HS, Huang HC, Lin LX. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis. Radiat Oncol 2019;14:178. [PMID: 31623639 DOI: 10.1186/s13014-019-1386-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
27 Hulshof MCCM, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, Nuyttens JJME, van der Sangen MJC, Jeene PM, Reinders JG, van Berge Henegouwen MI, Thano A, van Hooft JE, van Laarhoven HWM, van der Gaast A. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol 2021;39:2816-24. [PMID: 34101496 DOI: 10.1200/JCO.20.03697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
28 van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15:235-249. [PMID: 29235549 DOI: 10.1038/nrgastro.2017.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
29 Hirano H, Boku N. The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma. Asia Pac J Clin Oncol 2018;14:291-9. [PMID: 29873183 DOI: 10.1111/ajco.12995] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Jeene PM, van Laarhoven HWM, Hulshof MCCM. The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer. Best Pract Res Clin Gastroenterol 2018;36-37:53-9. [PMID: 30551857 DOI: 10.1016/j.bpg.2018.11.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
31 Chen Y, Zhu HP, Wang T, Sun CJ, Ge XL, Min LF, Zhang XW, Jia QQ, Yu J, Yang JQ, Allgayer H, Abba ML, Zhang XZ, Sun XC. What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis. Oncotarget 2017;8:89095-107. [PMID: 29179502 DOI: 10.18632/oncotarget.18760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
32 Li C, Tan L, Liu X, Wang X, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Wang X, Bi N, Deng L, Wang W, Zhang T, Ni W, Chang X, Han W, Xiao Z. Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. Front Oncol 2021;11:618776. [PMID: 34235073 DOI: 10.3389/fonc.2021.618776] [Reference Citation Analysis]
33 Yu Y, Zheng H, Liu L, Li H, Zheng Q, Wang Z, Wu Y, Li J. Predicting Severe Radiation Esophagitis in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy: Construction and Validation of a Model Based in the Clinical and Dosimetric Parameters as Well as Inflammatory Indexes. Front Oncol 2021;11:687035. [PMID: 34249736 DOI: 10.3389/fonc.2021.687035] [Reference Citation Analysis]